ARS Pharmaceuticals, Inc. (SPRY)

NASDAQ: SPRY · Real-Time Price · USD

5.51

-0.88 (-13.71%)

At close: Aug 20, 2026, 4:00 PM EDT

5.51

0.00 (0.00%)

After-hours: Aug 20, 2026, 4:10 PM EDT

ARS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	8.16	41.32	50.82	70.97	210.52	60.06
Short-Term Investments	135.68	203.67	263.21	157.39	63.86	-
Cash & Short-Term Investments	143.85	244.99	314.02	228.36	274.38	60.06
Cash Growth	-40.10%	-21.98%	37.51%	-16.77%	356.82%	144.94%
Accounts Receivable	46.84	25.35	8.18	-	-	-
Other Receivables	0.8	1	1	0.69	1.01	0
Receivables	47.64	26.35	9.18	0.69	1.01	0
Inventory	11.69	8.37	5.21	-	-	-
Prepaid Expenses	8.34	5.19	5.89	2.03	2.31	0.67
Other Current Assets	-	-	-	0.65	-	-
Total Current Assets	211.51	284.9	334.3	231.73	277.7	60.73
Property, Plant & Equipment	2.09	2.47	1.07	0.82	0.77	0.69
Other Intangible Assets	13.9	14.45	7.37	0.62	-	-
Other Long-Term Assets	22	25.84	8.42	0.02	2.96	0.02
Total Assets	249.5	327.65	351.15	233.19	281.44	61.45

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	5.2	9.16	14.13	0.76	1.66	1.79
Accrued Expenses	27.03	10.05	2.47	0.36	2.1	1.3
Current Portion of Long-Term Debt	-	-	-	-	-	3.48
Current Portion of Leases	-	-	-	0.24	0.23	0.14
Current Income Taxes Payable	-	-	-	-	0.17	-
Current Unearned Revenue	0.54	0.61	0.56	-	0.28	1.46
Other Current Liabilities	28.1	19.33	6.29	1.04	1	0.02
Total Current Liabilities	60.86	39.15	23.44	2.39	5.44	8.19
Long-Term Debt	171.6	168.51	69.38	-	-	4.93
Long-Term Leases	-	-	-	0.04	0.25	0.48
Long-Term Unearned Revenue	1.12	1.13	1.53	-	2.85	3
Other Long-Term Liabilities	3.4	4.61	-	-	-	0.08
Total Liabilities	236.98	213.39	94.36	2.43	8.55	16.68

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-In Capital	430.2	408.73	379.87	362	349.41	10.98
Retained Earnings	-417.56	-294.6	-123.31	-131.3	-76.94	-42.26
Comprehensive Income & Other	-0.14	0.13	0.22	0.05	0.41	-
Total Common Equity	12.51	114.26	256.8	230.76	272.89	-31.27
Shareholders' Equity	12.51	114.26	256.8	230.76	272.89	44.77
Total Liabilities & Equity	249.5	327.65	351.15	233.19	281.44	61.45

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	171.6	168.51	69.38	0.27	0.48	9.03
Net Cash (Debt)	-27.76	76.47	244.64	228.09	273.9	51.03
Net Cash Growth	-	-68.74%	7.26%	-16.73%	436.74%	251.86%
Net Cash Per Share	-0.28	0.78	2.39	2.40	6.86	1.77
Filing Date Shares Outstanding	99.45	99.3	98.12	96.5	94.4	25.7
Total Common Shares Outstanding	99.44	99.29	97.95	96.41	93.94	25.7
Working Capital	150.65	245.75	310.86	229.34	272.26	52.54
Book Value Per Share	0.13	1.15	2.62	2.39	2.90	-1.22
Tangible Book Value	-1.39	99.81	249.43	230.14	272.89	-31.27
Tangible Book Value Per Share	-0.01	1.01	2.55	2.39	2.90	-1.22
Machinery	-	-	-	0.67	0.38	0.09
Leasehold Improvements	-	-	-	0.02	-	-

SEC Filings: 10-K · 10-Q